Production method of combined streptococcosis and pseudomonosis vaccine for polar foxes and foxes
FIELD: medicine; veterinary science.
SUBSTANCE: strains Streptococcus pyogenes No 289 and Pseudomonas aeruginosa No 5292, 4762, 5271, 5211, and 5002 are grown up separately, inactivated and added with adjuvant. Thereafter produced monovaccines are mixed in equal ratio. Herewith used are daily culture of strain Streptococcus pyogenes No 289 containing 106x0.5 million micr.kl., strain Pseudomonas aeruginosa No 5292 with titre in "РТГА" 1:512, strains Pseudomonas aeruginosa No 4762 and No 5271 - with titre in "РП" 1:16, strains Pseudomonas aeruginosa No 5211 and No 5002 with titre in "РП" 1:16.
EFFECT: prevention of losses in reproduction of fur-bearing animals within farms with unfavourable streptococcal and pseudomonas infection conditions.
The essence of the invention. For the manufacture of a vaccine against Streptococcus and Pseudomonas foxes and foxes separately cultivated strain of Streptococcus pyogenes No. 289 and Pseudomonas aeruginosa No. 5292, 4762, 5271, 5211, 5002. All received supernatant subjected to inactivation by means of dimethylethanamine (EIA) at concentrations of 0.5%, pH 7.2 and exposure to 18 hours. Inactivity neutralized with Na thiosulfate (concentration of 1.5%"). In each supernatant was added adjuvant aluminium hydroxide 2 mg/10 ml of the vaccine. Supernatant together in one container in equal amounts. From cultures of Streptococcus positive on the M-factor of pathogenicity, preparing the hydrochloric acid extract by the method of Lansfeld. the pH of the extract with sodium hydroxide to 7.2 inactivate at 100°C. To inaktivirovannaja extract add adjuvant aluminium hydroxide (20 mg/10 ml
Received vaccines are combined into one container in equal amounts. Received the associated vaccine provides immunity formation 14 days after immunization of laboratory animals. The vaccine is injected females foxes and foxes before the rut, resulting in young creates immunity that persists for 6 months after birth.
The invention relates to the field of biotechnology and veterinary medicine and is intended for the production WACC is the R-drug streptococcosis and Pseudomonas.
Streptococcus and Pseudomonas infection is ubiquitous, cause significant economic damage to the farming and pose a danger to people's health.
In fur farms are registered each year of entitiy among foxes and polar foxes. The streptococcosis and Pseudomonas registered as individually and in Association. Die young in the pre-registration period (up to 30%). Females abortivum in the second half of pregnancy (30%). Pathology in Pseudomonas aeruginosa and streptococcal infections in animals are very diverse - damage to the reproductive system, septic processes in the body, lesions of the mammary glands, etc. foxes and Arctic foxes it occurs with lesions of the genitalia and is accompanied by resorption of embryos, proputovanju females. In this regard, specific prevention of the above diseases is required.
Currently, in our country there is no specific prophylaxis of Streptococcus foxes and foxes, as well as comprehensive prevention streptococcosis and Pseudomonas foxes and polar foxes. However, the known method of obtaining a vaccine against Streptococcus nutria, as well as the associated vaccine Streptococcus and pasteurellosis nutria, prepared on the basis of strain Str.Zooepiodemicuis VGNKI # K-D E R and P. multociola VGNKI No. 6011, 2394, 1015.
The aim of the present invention is to strairway associated immunogenic vaccines against Streptococcus and Pseudomonas foxes and polar foxes. The causative agent of Pseudomonas has Serafimovo variability, therefore, the effectiveness of specific prophylaxis is determined by polivalentes antigenic composition of the vaccine components.
Strains of Pseudomonas aereuginosa No. 5271and 5292intended as producers of proteolytic enzymes (alkaline protease and elastase), strains No. 4762, 5211, 5002, 5292as producers of exotoxin And in the manufacture of specific immune drug against Pseudomonas aeruginosa infection of foxes and polar foxes.
A strain of Streptococcus pyogenes No. 289 group And positive for M-protein, which is linked to the virulence and immunogenicity of microbial cells, used as a producer streptococcal antigen M-protein in the manufacture of specific immune drug with streptococcal infection.
In fur farms annually hosts a series of events on specific prevention of young foxes and foxes against a range of infectious diseases: plague, Pseudomonas, dermatophytosis, salmonellosis, colibacillosis. Immunization against Streptococcus still was not conducted because of the lack of vaccine streptococcosis fur-bearing animals.
The aim of the present invention is to construct the associated immunogenic vaccines against Pseudomonas of streptococcosis foxes and foxes, to complement the existing system of prevention and Wellness activities and to achieve more effective epidemic control streptococcosis and Pseudomonas young foxes and foxes.
A vaccine for the prevention of Pseudomonas and Streptococcus foxes and foxes were prepared on the basis of strains of Pseudomonas aereuginosa No. 5292, 4762, 52715211, 5002and strain of Streptococcus pyogenes No. 289 of the group And that are isolated from females of the Fox and deposited in the collection of strains of pathogens diseases of fur-bearing animals of the Museum of bacterial and viral cultures research Institute fur farming and breeding (NIPSC). C. A. Afanasyeva and have registration numbers 25 and 14.
For the preparation of a series of vaccines Pseudomonas and Streptococcus used vials with lyophilized culture of Streptococcus group a strain 289 and Pseudomonas aereuginosa No. 5292, 521, 52714762, 5002.
Example 1. Streptococcus pyogenes strain No. 289 type And were grown for 24 hours at 37°0.5 - liter bottles on the BCH with 1% glucose. Tested for purity culture in MPA and MPB. Checked the purity of the growth in view of smears stained by Gram.
Checked the presence of M-protein by the method of "passing through the blood". To do this in a test tube with 5 ml of fresh blood to be tested in the absence of M-antibodies centuries the Dili 0.5 ml daily culture of Streptococcus, contains 106x 0.5 ml microbial cells, and incubated 24 hours at 37°C.
Smears examined on the contents of streptococcal culture. The presence of M-protein was determined by the ability of the strain to grow in human blood. The daily culture were sown in 500 ml flasks with broth Todd-Hewitt and incubated for 12 hours at 37°C. When determining optical turbidity standard of SCI them. Tarasevich in 1 ml of culture 4 billion microbial cells - 4x109.
The culture was centrifuged at 1500g for 30 minutes. The supernatant from each vial was decanted, and the residue resuspendable in 50 ml of saline solution, vials suspension warmed up in a water bath at 56°With 30 minutes. After inactivation of the culture samples from each vial was tested for sterility on MPA and MPB. From inactivated suspensions were prepared acidic extract on Lansfeld. To do this, vials suspension was centrifuged at 1500g for 30 minutes. The supernatant liquid was decanted, the precipitate resuspendable with the addition of 0.35 ml of 1 n HCl. Then the bottles are warmed up with 100°10 minutes.
the pH of hydrochloric acid extract was brought to 7.0±0,2 solution of sodium hydroxide at a concentration of 1.0 mol/L. Extract was centrifuged at 1500g for 30 minutes.
The supernatant from each vial was tested for sterility on MPA, MPB, MPB within 10 days.
The supernatant fluid is here collected in one bottle, again checked for sterility by MPA, MPB, MPB and kept at 4°C.
Crops should not have growth within 10 days. After checking vaccine sterility in capacity was added adjuvant - 10% of the total volume of 3% solution of hydrate of aluminum oxide. The contents were thoroughly stirred. Three days after making the adjuvant have formed a series of ready single. pH single must be in the range of 7.0 to 7.2. Prepared a series of single tested for sterility on MPA, MPB, MPB. The vaccine was tested for safety 5 Guinea pigs and 10 white mice, which were injected subcutaneously respectively of 2.0 and 0.5 ml. If laboratory animals within 7 days was not observed painful deviations from the norm, the vaccine is considered to be harmless. A series of the vaccine was tested for activity. 10 white mice were administered 0.5 ml of the vaccine. 30 days after immunization 10 immune and 10 control mice infected with podarowano lethal dose of Streptococcus containing 10 LD50-10 (105x 0.2 ml). Within seven days observed. All mice remained alive, i.e. the safety was 100%. The vaccine is immunogenic, if you remain healthy 80% of mice.
Example 2. For the preparation of a series of vaccines Pseudomonas prepared single of the 5 strains used separately. Each strain was tested for contamination with other micro is Laura by crops in MPA, BCH CP, Saburo according to the standard technique. Through two days of the colony acquired a greenish-bluish color, agar acquired color pigment pyocyanin, MPA under vaseline oil growth was absent. Each serotype were tested for pathogenicity by intramuscular infection 2 foxes daily broth culture grown on MPA at 37°Spri determining optical turbidity standard of SCI them. Tarasevich in 1 ml of culture used to prepare the vaccine should contain at least 500 ml of microbial cells. The infected foxes in the injection area within 24-72 hours there is swelling, fever, lameness. Of all the strains used were prepared supernatant. Strain 5292(producer exotoxin A) was grown in enriched broth Martin. Exotoxin must be in rtga titer in a dilution of 1:512
Strains 5211, 5002(producers of alkaline protease) were grown on lio-fileserving environment Lensen. When the control supernatant alkaline protease must be detected in dilutions of at least 1:32 in the TL. Strains 4762, 527 (producers elastase) were cultured on dried environment Lensen. When the control RP title is set in dilutions of 1:16.
All received supernatant was subjected to inactivation using dime-tiletamine (EIA) at concentrations of 0.5%, pH 7.2 expozitii 18 hours. After 18 hours, add sodium thiosulfate (final concentration of 1.5%) to neutralize inactivant. The inactivation efficiency was checked by plating on plates with TSA, BCH, MPA and cetrimide agar. The growth media should be absent.
Each supernatant was injected 5 Guinea pigs subcutaneously 3.0 ml and 10 white mice at 1.0 ml intraperitoneally. The observations were carried out within 7 days. During the observation lethargy, weight loss and death of animals was not available. In each supernatant was added to the aluminum hydroxide at the rate of 2 mg/10 ml
After 18 hours supernatant tested for sterility on MPA, MPB. Then supernatant combined in one container in equal amounts. Received the polio tested for sterility on MPA, MPB. The protective properties of poliomyelitis was tested on mice. For that 30 days after immunization 10 immunized and 30 control mice were infected each sarovaram. When infected mice 4 LD50the safety of their 30 days should be 90-100%.
Example 3. Then prepared a series of associated vaccine. To this end received inactivated vaccine combine one container. the pH of the finished vaccine should be around 7.0 to 7.2. The vaccine was tested for sterility on the BCH, MPA, MPB and environment Saburo. The filling of vaccines produced in 100 ml sterile vials are closed with rubber p is Okami and rolled aluminum caps, ensuring the integrity of the package contents of the bottles.
To determine the quality of the associated vaccine made a selection of different series in the amount of 10 bottles, of which 5 are used for testing, and 5 bottles are kept in the archives of the state Comptroller within 12 months. To determine the appearance, color, presence of any impurities, cereals, mold, underdeveloped sediment vaccine vials thoroughly shaken and looking at visually in transmitted light. At the same time the bottles are checked for tightness and correct labeling.
The concentration of hydrogen ions determine the electrometric method using the potentiometer brand HCS-01 or other device of the same accuracy class. For testing use 3 of the vaccine vial. The contents of each vial experience separately. Determination of pH of vaccines is conducted according to instructions attached to the potentiometer. The vaccine should have a pH around 7.0 to 7.2.
To test for sterility using 5 vials of vaccine. The crops is carried out from each bottle in two test tubes with MPA, MPB, MPB and environment Saburo. The nutrient medium from cultures incubated for 10 days, the growth of microorganisms should not be. The safety of vaccines check on white mice weighing 16-18 g and Guinea pigs weighing 300-350 g this is sportsouth 3 vial of vaccine. From each selected 20-30 ml and mix in one bottle in the overall sample, using to determine the safety and immunogenicity.
To determine the safety of 5 Guinea pigs subcutaneously in the back inject 2.0 ml and 10 white mice in the back area of 0.5 ml Vaccine should not cause disease and death in laboratory animals for 10 days of observation.
To determine the protective activity of 40 white mice weighing 16-18 g in the back injected with 0.2 ml of vaccine. 14 days after immunization 20 vaccinated and 20 control mice of the same weight infect subcutaneously in the thigh podarowano ten times the lethal dose of vaccine strain of streptococci and each strain of Pseudomonas aeruginosa (20 mice). The observation period of 10 days. The vaccine is considered immunogenic if it protects from disease and the deaths of at least 18 immunized mice in each group with the disease in all mice in the control groups for 10 days.
The method of manufacture of associated vaccine against Streptococcus and Pseudomonas foxes and foxes, characterized in that the separately grown strains of Streptococcus pyogenes No. 289 and Pseudomonas aeruginosa No. 5292, 4762,5271, 5211, 5002, disable and add adjuvant, and then the single mixed in equal proportions, p and use this daily culture of a strain of Streptococcus pyogenes No. 289, contains 106·0.5 million microl, a strain of Pseudomonas aeruginosa No. 5292with a title in rtga 1:512, strains of Pseudomonas aeruginosa No. 4762and No. 5271- with a title in SPM 1:16, strains of Pseudomonas aeruginosa No. 5211and # 5002with a title in SPM 1:16.
SUBSTANCE: during acute period of purulent meningitis (BPM) additionally, Wobenzyme is prescribed in daily dose 1 tablet per 6 kg of body weight 3 times a day within 10 days simultaneously with antibacterial therapy. Treatment of meningococcal and pneumococcal meningitis is ensured with prescribed benzylpenicillin in daily dosage 300 thousand units/kg. Haemophilic meningitis is treated by prescribed Ceftriaxone in daily dose 100 mg/kg.
EFFECT: higher efficiency of BPM specific therapy due to Wobenzyme ability to improve antibiotic penetration through blood-brain barrier and transport to inflammatory tissue and autointoxication reduction.
3 cl, 2 tbl, 4 ex
SUBSTANCE: invention concerns peptide compounds representing an amino acid sequence X1KEFX2RIVX3RIKX4FLRX5LVX6, where X1 is N-end segment which is IG; X2 is K or E; X3 is Q or E; X4 is D or R; X5 is N or E; X6 is C-end segment, which is a sequence selected out of PRTE or RPLR; where N-end segment is acetylated and/or C-end segment is amidated; with affinity to toxins, particularly to bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. These compounds can inhibit or neutralise toxins. Invention also concerns pharmaceutical compositions and application of the claimed compounds in prevention or treatment of diseases or states caused by fungi or bacterial infection.
EFFECT: obtaining compounds for prevention or treatment of diseases or states caused by fungi or bacterial infection.
12 cl, 4 tbl, 4 ex
FIELD: medicine; biotechnologies.
SUBSTANCE: vaccine drug includes deactivated Escherichia coli bacteria of strain No 389 (078) and auxiliary substances. Additionally the drug includes aminoethylethyleneimine and liposome-forming mix as auxiliary substance at the following component rate in fluid form, wt %: aminoethylethyleneimine - 0.5-3; liposome-forming mix - 7.3-15; suspension of deactivated Escherichia coli bacteria of serotype 078 - 82.0-91.5.
EFFECT: harmless for fowl, enhanced antigenic and immunogenic activity.
3 cl, 4 tbl, 6 ex
FIELD: medicine; veterinary.
SUBSTANCE: medicine includes metal iodine and potassium iodide, prolongator and water. 1,2-propylene glycol is used as prolongator, and additionally vitamin A (retinol acetate), vitamin E (alpha-tocopherol acetate), vitamin B1 (thiamine hydrochloride), vitamin B2 (riboflavin), vitamin B6 (pyridoxine hydrochloride), vitamin B12 (cyanocobalamin), iron carbonate, magnium phosphate, manganese sulfate, copper sulfate, zinc sulfate, cobalt chloride, sodium chloride, amber acid, glucose, rectified ethyl alcohol (96%) are applied. Medicine components are taken at the following rate, g/100 ml of distilled water: metal iodine, chemically pure 0.112-0.187; potassium iodide, R 0.337-0.562; vitamin E (alpha-tocopherol acetate) 0.060-0.100; vitamin A (retinol acetate) 3.750-6.250 thousand mass units; vitamin B1 (thiamine hydrochloride) 0.052-0.087; vitamin B2 (riboflavin) 0.037-0.062; vitamin B6 (pyridoxine hydrochloride) 0.034-0.056; vitamin B12 (cyanocobalamin) 0.026-0.044; iron carbonate, R 0.337-0.562; magnium phosphate, R 0.337-0.562; manganese sulfate, R 0.172-0.287; copper sulfate, R 0.090-0.150; zinc sulfate, R 0.315-0.525; cobalt chloride, R 0.071-0.119; sodium chloride, R 0.589-0.981; amber acid, primary standard 0.225-0.375; glucose, AR 0.172-0.287; rectified ethyl alcohol (96%) 0.300-0.500 ml; 1,2- propylene glycol 0.900-1.500 ml. Method involves medicine administration with fodder in dosage of 1.00-1.50 mg per 1 kg of fish weight once per day for 5-7 days.
EFFECT: correction of needs for bioactive substances, prevention of avitaminosis, achievement of high antioxidant organism protection level, prevention of accumulation of non-saturated fatty acid peroxides harmful to fish.
2 cl, 3 tbl, 3 ex
FIELD: medicine; pharmacology.
SUBSTANCE: invention is used for treatment of bacteriemic infections, it is prepared as composition in the form of dry powder, adapted for delution by water with reception of the suspension important pH in a range from approximately 5.0 to approximately 5.5 at initial delution and which in addition contains the stabilizer pH which represents sodium-carboxymethyl cellulose. Besides, the invention concerns application sodium-carboxymethyl cellulose for reduction of degree of degradation clavunalate and for stabilisation pH the received suspension.
EFFECT: stability improvement in preparation.
7 cl, 1 dwg, 1 tbl
SUBSTANCE: method is implemented as follows: bacterial-enzymatic probiotic "Balance-narine-f" is introduced locally and orally in combination with inhalation of negative air ions.
EFFECT: allows for decrease of complications and higher efficiency of treatment.
1 tbl, 3 ex
SUBSTANCE: sterile aqueous inhalation solution containing active substance Tobramycine. Preparation of invention is offered with high content of active substance (approximately 80 to 120 mg/ml Tobramycine). Preparation also contains acid adjuvant and has low content of sodium chloride (maximum approximately 2 mg/ml). Preparation can be injected or introduced as aerosol with e.g. common sprays.
EFFECT: suitable for application in combination with recent sprays with vibrating membrane and gives the chance for application of an individual therapeutic dose.
24 cl, 1 tbl, 7 ex
SUBSTANCE: antibacterial and rehydration therapies are combined with prescribed sorbents, symptomatic therapy. From first day of disease prescribed is infusion herb collection consisting of silverweed rhizome, salvia leaves, milfoil herb, St. John's wort herb, inula rhizomes with roots, tickseed herbs, mint leaves, fennel fruits and buckthorn bark at ratio of components 2:2:2:2:2:2:2:2:1. Infusion is taken up dosed 1\3 glass 3 times a day, 30 min before meal within 10 days. Then within three weeks after basic therapy appoint infusion from silverweed rhizome, salvia leaves, milfoil herb.
EFFECT: provides accelerated normalisation of clinical-laboratory indicators, and prevention of infectious complications without by-effects.
2 cl, 1 tbl, 1 ex
FIELD: medicine; biotechnologies.
SUBSTANCE: strain Lactobacillus casei FERM BP-100059 (FERM P-19443), possessing probiotic properties; grow up in the presence of any from one to four amino acids as a source of the nitrogen necessary for growth. At planting in suitable cultural to medium, the final value pH makes 4.0 or lower, and the highest acidity makes 1.5% or above. The strain resistable is to 5% salts of cholic acids. The strain produces an antibiotic. On the basis of the strain as the active beginning, the lactobacillus preparation of probiotic action for humans, animals and plants and the preventive or therapeutic agent against human, animal and plant infections.
EFFECT: ability to colonise and breed in the centres chronic the infections, steady against treatment, strong clearing action and destruction causing a bacterium infection.
12 cl, 5 dwg, 56 tbl, 34 ex
FIELD: medicine; pharmacology.
SUBSTANCE: peroral pharmaceutical dosed out form for treatment of the conditions bound to secretion of acid in a stomach, includes an acid-sensible inhibitor of the proton pump and antagonist of H2-molecular switchers, with the delayed and-or prolonged liberation of the proton pump acid-sensible inhibitor, and fast liberation of antagonist of H2-molecular switchers.
EFFECT: maximum suppression of acid in a stomach after the first dose and throughout all course of treatment.
69 cl, 4 dwg, 7 ex
FIELD: medicine; pharmacology.
SUBSTANCE: essence of the invention includes selection of the damaged organs from the dead nutrias from the local epidemical centre from which prepare suspension, perform bacterial inoculation in differenrial diagnostic mediums, separate pure cultures of originators of colibacillosis, salmonellosis and enterococcus infections, separately grow up cultures Escherichia coli. Salmonella typhimurium and Streptococcus, fecalis in a meat infusion agar with addition of 0.2% of a glucose with titer 4-5 billion microbic cells in 1 cm3, inactivate by entering of formalin to 0.4-0.6 % final concentration, condition at temperature 37°C within 72-96 hours, admix cultures in equal parities, then bring a solution of a aluminium hydroxide in amount of 20% to the volume, carefully admix, pack up and cork.
EFFECT: increase of an adjuvanticity of a vaccine.
SUBSTANCE: invention concerns medicine, particularly an immunogenic composition capable of activating immune response to poliomyelitis virus. The invention claims an immunogenic composition including deactivated poliomyelitis virus, bacterial polysaccharide or oligosaccharide and stabiliser, in the dried form. After recovery the composition can activate immune response to poliomyelitis virus. The invention also concerns a method for obtaining the claimed composition.
EFFECT: obtaining immunogenic composition capable of activating immune response to poliomyelitis virus and including deactivated poliomyelitis virus.
32 cl, 15 ex, 11 tbl, 2 dwg
SUBSTANCE: invention relates to medicine and pediatrics. The method consists of clinical examination of a child and carrying out of therapeutic procedures. There are determined abnormalities in immunologic state of main cell markers: total leukocyte count, lymphocytes CD3, CD4, CD4/CD8, CD19, classes A, M, G of antibodies levels; antibodies to chlamydia, HSV (herpes simplex virus), CMV (cytomegalovirus), toxoplasma, toxocaria, lamblia, opisthorchis. Drug dosage regimen for children under four years is as follows: polyoxidonium intranasal by 5 drops 30 minutes before meal once a day for 2 days, then 2 days break, the course total duration is 20 days; administration of succinic acid by 25 mg after meal in the morning and at noon for 5 days, then 2 days break. Children four to seven years proposed to take bronchomunal P by 3.5 mg before meal every morning for 1 month; succinic acid by 50 mg twice a day as above; and ribomunil by 75 mg before meal in the morning, during first month on 4 first days of each week, and during 2nd to 6th months on 4 first days of each month. Regimen for children seven to eleven years is as follows: cyclopheron 12.5% by 2 ml once a day on 1st, 2nd, 3rd, 4th, 6th, 8th, 11th, 14th, 17th, 21st, and 25th day, then once a week for 2 months; methyluracil by 50 mg after meal three times a day for 1 month; cod-liver oil with garlic by 1 dragee after meal three times a day for 10 days; and succinic acid by 75 mg twice a day as above. Regimen for children eleven to sixteen years is as follows: timaline by 0.01 g intramuscularly by 2 ml for 20 days; cod-liver oil with garlic by 2 dragee after meal three times a day for 10 days; biologically active additive "Karvipar" by 1 dessert-spoon three times a day for 2 weeks; and succinic acid by 100 mg twice a day as above. Immune state correction course is carried out in late autumn and in early spring, in other time polyvitamins are administered every month.
EFFECT: providing of health state stabilisation in ICP children, reducing any complications.
1 tbl, 4 ex
FIELD: medicine; veterinary science.
SUBSTANCE: agent contains mixed suspensions of bacteria strain and protective medium. As protective medium, agent contains saccharose-gelatin composition with the following ratio of mixture (mass%): saccharose - 15, gelatin - 5, 9% sodium chloride solution - 80. As suspensions of bacteria strain, agent contains suspension of the following strains (mass%): Azomonas agilisc B-2586 - 8, Azotobacter chroococcum B-3162 - 7, Azotobacter vinelandii B-2587 - 7, Bacillus subtillis B-5225 - 7, Bacillus subtillis B-4828 - 9, Bifidum bacterium globosum B-2584 - 10, Escherichia coli B-4412 - 8, Enterococcus faecium B-2898 - 7, Lactobacillus acidophilus B-3488 - 7, Lactobacillus acidophilus B-2585- 7, Propionibacte-rium freudenreichii B-6561- 7, Pseudomonas sp. B-3908 - 7, Pseudomonas sp. B-2589- 7, Saccharomyces cerevisiae Y-365 - 2.
EFFECT: agent enables to normalize bowel microbiocenose of healthy animals and birds; reduce mortality and to provide mass increase of young animals.
1 tbl, 3 ex
FIELD: veterinary medicine.
SUBSTANCE: it is necessary to select the affected organs from dead nutrias out of local epizootic focus, prepare the suspension out of pathological material to inoculate onto differential-diagnostic media, isolate pure cultures of Escherichia coli, Salmonella typhimurium, Streptococcus pneumoniae and Streptococcus fecalis, grow separately the isolated cultured in beef-extract nutritive medium at addition of 0.2%-glucose to achieve the concentration of microbial cells of about 4-5 bln/cu/ cm, inactivate with formalin up to 0.4-0.6%-final concentration, keep at 37°C for about 72-96 h, mix the cultures at equal ratios, add 3%-aluminum hydroxide solution at the quantity of 20% against the volume of the culture to be thoroughly mixed. Then the vaccine obtained should be packed and sealed. The innovation is simple in usage, moreover, it enables to increase specificity and immunogenicity of the obtained vaccine.
EFFECT: higher efficiency.
FIELD: veterinary medicine.
SUBSTANCE: the vaccine suggested contains as antigens: the cell suspension of pure cultures of Escherichia coli, Salmonella typhimurium and Streptococcus fecalis obtained due to selecting the affected organs from dead nutrias out of local epizootic focus, preparing the suspension, inoculation onto differential-diagnostic media, isolating pure cultures of the agents of Escherichia coli, Salmonella typhimurium and Streptococcus fecalis. The obtained pure cultures of microorganisms should be separately grown in beef-extract broth with glucose up to the concentration of microbial cells being 4-5 bln/cu. cm to be then mixed at equal ratios. The vaccine, also, contains formalin, glucose and aluminum hydroxide at the following ratio of the components, weight%: cell suspension of Escherichia coli pure culture isolated from the affected organs out in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu. cm 18.0-21.0; cell suspension of Salmonella typhimurium pure culture isolated from the affected organs in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu. cm 18.0-21.0, cell suspension of Streptococcus pneumoniae pure culture isolated from the affected organs in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu/ cm 18.0-21.0 cell suspension of Streptococcus fecalis pure culture isolated from the affected organs in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu. cm 18.0-21.0, glucose 2.0-1.0; formalin 2.0-1.5; aluminum hydroxide - the rest. The vaccine in question is of high specificity, safety and immunogenicity.
EFFECT: higher efficiency.
5 ex, 1 tbl
FIELD: microbiology, in particular production of associated pertusis, diphtheria, and tetanum vaccine.
SUBSTANCE: claimed method includes blending of pertusis component, diphtheria and tetanum anatoxins; mixture sorption on aluminum hydroxide; mixture dosage into container, mixture lyophilizing and container sealing. As pertusis component cell-free pertusis anatoxin in concentration of 40-50 mug/ml is used. Mixture of cell-free pertusis anatoxin, diphtheria and tetanum anatoxins is sorbed on aluminum hydroxide. Then polyoxydonium as immunomodulator in amount of 0,5-0,52 mug/g in introduced into abovementioned mixture, mixture is held for 18-20 h at 4-10°C, sucrose is added up to finish concentration and mixture is held for 1 h at 4-10°C.
EFFECT: vaccine of decreased reactogenicity.
2 ex, 1 tbl
SUBSTANCE: the resent innovation deals with mixing pertussis component, diphtheric and tetanus anatoxins and sorption of the mixture upon aluminum hydroxide followed by dosing the mixture into the tank, freeze drying the mixture and hermetic sealing of this tank, moreover, as pertussis component one should apply cell-free pertussis anatoxin; as for mixing cell-free pertussis anatoxin, diththeric and tetanus anatoxins it should be carried out simultaneously at availability of phosphate-buffered physiological solution; the mixture obtained should be kept for 1 h at about 4-10°C with subsequent sorption upon aluminum hydroxide; just before freeze drying the mixture should be supplemented with saccharose up to final concentration being 9-10.5%, then the mixture should be mixed and kept at about 4-10C for 1 h. The innovation enables to achieve decreased reactogeneity.
EFFECT: higher efficiency.
2 ex, 4 tbl
FIELD: veterinary microbiology, biotechnology.
SUBSTANCE: vaccine comprises inactivated purified chlamydium antigens from strains of species Chlamydia psittaci: MZ-89 - a pathogen of chlamydiosis meningoencephalitis in calves, 250 - a pathogen of chlamydiosis abortion in cows and SK-89 - a pathogen of chlamydiosis conjunctivitis in calves, These strains are grown in chicken embryo yolk and allantois envelopes simultaneously and taken in the ratio 0.25:0.25:0.25, respectively, and in the concentration of chlamydia 16-18 mg/ml adsorbed on potash alum and emulsified in oily-lanoline adjuvant with the content of 0.2% glutaraldehyde as a preserving agent. Proposed vaccine possesses broad immunogenic activity and broad spectrum of antigenicity in different clinical forms of diseases in cattle and sheep and goats.
EFFECT: enhanced and valuable properties of vaccine.
9 tbl, 4 ex
SUBSTANCE: vaccine comprises as antigens the cell suspension of pure cultures of pathogens of coli-bacteriosis Escherichia coli, salmonellosis Salmonella typhimurium and streptococcosus Streptococcus pneumoniae obtained by selection of damaged organs from dead nutrias and inoculation of cultures on differential-diagnostic media. Isolated pure cultures are grown separately in beef-extract broth with glucose to the concentration of microbial cells 4-5 billions in 1 cm3 followed by their mixing in equal ratio. Vaccine comprises formalin and aluminum hydroxide in the following ratio of components, wt.-%: cell suspension of pure culture of coli-bacteriosis pathogen Escherichia coli isolated from a local epizootic focus in nutrient medium with a titer 4-5 billions of microbial cells in 1 cm3, 24.0-29.0; cell suspension of pure culture of salmonellosis pathogen Salmonella typhimurium isolated from a local epizootic focus in nutrient medium with a titer 4-5 billions of microbial cells in 1 cm3, 24.0-29.0; cell suspension of pure culture of streptococcosus pathogen Streptococcus pneumonia isolated from a local epizootic focus in nutrient medium with a titer 4-5 billions of microbial cells in 1 cm3, 24.0-29.0; glucose, 1.0-2.0; formalin, 1.5-2.0, and aluminum hydroxide, the balance. Proposed vaccine shows high immunogenicity, high specificity and harmless.
EFFECT: valuable properties of vaccine.
1 tbl, 5 ex
FIELD: chemistry; biochemistry.
SUBSTANCE: invented here are proteins of the meningococcus bacteria Neisseria meningitides (mainly strain B), with immunogenic properties. The proteins have defined amino acid sequences, presented in the description, and are coded with corresponding nucleotide sequences. Description is also given of an antibody, specific to the indicated meningococcus proteins. These proteins, coding their nucleotide sequences, as well as the specific antibody, can be used as an active ingredient in compositions for treating or preventing infection caused by Neisseria meningitides. The presented proteins can be used as antigens for making effective vaccines, immunogenic compositions.
EFFECT: obtaining proteins, used as ingredients for making effective vaccines, immunogenic compositions.
11 cl, 2 tbl, 104 ex